Back
Immunovant, Inc. (IMVT)
BiotechnologyIMVT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$30.46
+0.61%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-2.77
ROE
-64.8%
Gross margin
0.0%
Debt/Equity
0.01x
Revenue growth
P/B ratio
Beta
Forward P/E
Immunovant, Inc. — company intelligence
Earnings surprises
Q1 2027$-0.75 vs $-0.63 est-19.5%
Q4 2026$-0.73 vs $-0.61 est-19.1%
Q3 2026$-0.61 vs $-0.73 est+16.3%
Q2 2026$-0.73 vs $-0.73 est+0.2%
Analyst consensus · 23 analysts
18 Buy5 Hold0 Sell
Updated Oct 6, 2026
Insider activity · 90 days
0 buys4 sellsnet -15,557 shares
Van Tuyl ChristopherSell 2,846 · Sep 23, 2026
Pande Atulother 1,500 · Aug 28, 2026
Gloria MelanieSell 3,056 · Aug 20, 2026
Recent SEC filings
4 — Insider transaction reportSep 25, 2026
8-K — Material event reportSep 3, 2026
4 — Insider transaction reportAug 28, 2026
Latest news
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session — Benzinga · 2d ago
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket — Benzinga · 2d ago
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next — Yahoo · 1w ago
Immunovant (IMVT) Just Gave Investors Something To Think About — Yahoo · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.